{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:27:35Z","timestamp":1789612055565,"version":"build-2803163510"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research, India","doi-asserted-by":"crossref","award":["R.12013\/16\/2024-HR"],"award-info":[{"award-number":["R.12013\/16\/2024-HR"]}],"id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10929-x","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T06:33:14Z","timestamp":1755325994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The quest for Parkinson\u2019s disease biomarkers: traditional and emerging multi-omics approaches"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6954-7579","authenticated-orcid":false,"given":"Pratibha","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6042-7469","authenticated-orcid":false,"given":"Rajinder K.","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"10929_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"JD Steinmetz","year":"2024","unstructured":"Steinmetz JD, Seeher KM, Schiess N et al (2024) Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global burden of disease study 2021. Lancet Neurol 23:344\u2013381. https:\/\/doi.org\/10.1016\/S1474-4422(24)00038-3","journal-title":"Lancet Neurol"},{"key":"10929_CR2","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1212\/CPJ.0000000000001016","volume":"11","author":"CH Adler","year":"2021","unstructured":"Adler CH, Beach TG, Zhang N et al (2021) Clinical diagnostic accuracy of early\/advanced Parkinson disease: an updated clinicopathologic study. Neurol Clin Pract 11:e414\u2013e421. https:\/\/doi.org\/10.1212\/CPJ.0000000000001016","journal-title":"Neurol Clin Pract"},{"key":"10929_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41531-023-00568-z","volume":"9","author":"M Tsalenchuk","year":"2023","unstructured":"Tsalenchuk M, Gentleman SM, Marzi SJ (2023) Linking environmental risk factors with epigenetic mechanisms in Parkinson\u2019s disease. Npj Park Dis 9:123. https:\/\/doi.org\/10.1038\/s41531-023-00568-z","journal-title":"Npj Park Dis"},{"key":"10929_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fneur.2019.00218","volume":"10","author":"N Ball","year":"2019","unstructured":"Ball N, Teo W-P, Chandra S, Chapman J (2019) Parkinson\u2019s disease and the environment. Front Neurol 10:218. https:\/\/doi.org\/10.3389\/fneur.2019.00218","journal-title":"Front Neurol"},{"key":"10929_CR5","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2018.3406","author":"J Guo","year":"2018","unstructured":"Guo J, Zhao X, Li Y et al (2018) Damage to dopaminergic neurons by oxidative stress in Parkinson\u2019s disease (Review). Int J Mol Med. https:\/\/doi.org\/10.3892\/ijmm.2018.3406","journal-title":"Int J Mol Med"},{"key":"10929_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/CON.0000000000000348","volume":"22","author":"NR McFarland","year":"2016","unstructured":"McFarland NR (2016) Diagnostic approach to atypical Parkinsonian syndromes. Contin Lifelong Learn Neurol 22:1117\u20131142. https:\/\/doi.org\/10.1212\/CON.0000000000000348","journal-title":"Contin Lifelong Learn Neurol"},{"key":"10929_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00305","volume":"10","author":"R He","year":"2018","unstructured":"He R, Yan X, Guo J et al (2018) Recent advances in biomarkers for Parkinson\u2019s disease. Front Aging Neurosci 10:305. https:\/\/doi.org\/10.3389\/fnagi.2018.00305","journal-title":"Front Aging Neurosci"},{"key":"10929_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant D-E et al (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s progression markers initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22:407\u2013417. https:\/\/doi.org\/10.1016\/S1474-4422(23)00109-6","journal-title":"Lancet Neurol"},{"key":"10929_CR9","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1007\/s00415-023-11810-2","volume":"270","author":"JS Middleton","year":"2023","unstructured":"Middleton JS, Hovren HL, Kha N et al (2023) Seed amplification assay results illustrate discrepancy in Parkinson\u2019s disease clinical diagnostic accuracy and error rates. J Neurol 270:5813\u20135818. https:\/\/doi.org\/10.1007\/s00415-023-11810-2","journal-title":"J Neurol"},{"key":"10929_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr015","volume":"134","author":"I Devic","year":"2011","unstructured":"Devic I, Hwang H, Edgar JS et al (2011) Salivary \u03b1-synuclein and DJ-1: potential biomarkers for Parkinson\u2019s disease. Brain 134:e178\u2013e178. https:\/\/doi.org\/10.1093\/brain\/awr015","journal-title":"Brain"},{"key":"10929_CR11","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3390\/antiox9070597","volume":"9","author":"K-H Chang","year":"2020","unstructured":"Chang K-H, Chen C-M (2020) The role of oxidative stress in Parkinson\u2019s disease. Antioxidants 9:597. https:\/\/doi.org\/10.3390\/antiox9070597","journal-title":"Antioxidants"},{"key":"10929_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","volume":"18","author":"Y Hasin","year":"2017","unstructured":"Hasin Y, Seldin M, Lusis A (2017) Multi-omics approaches to disease. Genome Biol 18:83. https:\/\/doi.org\/10.1186\/s13059-017-1215-1","journal-title":"Genome Biol"},{"key":"10929_CR13","doi-asserted-by":"publisher","first-page":"9547","DOI":"10.3390\/ijms24119547","volume":"24","author":"E Paccosi","year":"2023","unstructured":"Paccosi E, Proietti-De-Santis L (2023) Parkinson\u2019s disease: from genetics and epigenetics to treatment, a miRNA-based strategy. Int J Mol Sci 24:9547. https:\/\/doi.org\/10.3390\/ijms24119547","journal-title":"Int J Mol Sci"},{"key":"10929_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jns.2014.12.017","volume":"349","author":"Y Feng","year":"2015","unstructured":"Feng Y, Jankovic J, Wu Y-C (2015) Epigenetic mechanisms in Parkinson\u2019s disease. J Neurol Sci 349:3\u20139. https:\/\/doi.org\/10.1016\/j.jns.2014.12.017","journal-title":"J Neurol Sci"},{"key":"10929_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2017.12.007","volume":"42","author":"H Deng","year":"2018","unstructured":"Deng H, Wang P, Jankovic J (2018) The genetics of Parkinson disease. Ageing Res Rev 42:72\u201385. https:\/\/doi.org\/10.1016\/j.arr.2017.12.007","journal-title":"Ageing Res Rev"},{"key":"10929_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s13311-013-0211-8","volume":"10","author":"N Ammal Kaidery","year":"2013","unstructured":"Ammal Kaidery N, Tarannum S, Thomas B (2013) Epigenetic landscape of Parkinson\u2019s disease: emerging role in disease mechanisms and therapeutic modalities. Neurotherapeutics 10:698\u2013708. https:\/\/doi.org\/10.1007\/s13311-013-0211-8","journal-title":"Neurotherapeutics"},{"key":"10929_CR17","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/cells11213439","volume":"11","author":"S Younesian","year":"2022","unstructured":"Younesian S, Yousefi A-M, Momeny M et al (2022) The DNA methylation in neurological diseases. Cells 11:3439. https:\/\/doi.org\/10.3390\/cells11213439","journal-title":"Cells"},{"key":"10929_CR18","doi-asserted-by":"publisher","first-page":"1123621","DOI":"10.3389\/fcell.2023.1123621","volume":"11","author":"H Song","year":"2023","unstructured":"Song H, Chen J, Huang J et al (2023) Epigenetic modification in Parkinson\u2019s disease. Front Cell Dev Biol 11:1123621. https:\/\/doi.org\/10.3389\/fcell.2023.1123621","journal-title":"Front Cell Dev Biol"},{"key":"10929_CR19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1093\/aje\/kwad082","volume":"192","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Ray A, Portengen L et al (2023) Metal exposure and risk of Parkinson disease: a systematic review and meta-analysis. Am J Epidemiol 192:1207\u20131223. https:\/\/doi.org\/10.1093\/aje\/kwad082","journal-title":"Am J Epidemiol"},{"key":"10929_CR20","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/ana.26897","volume":"95","author":"SA Sakowski","year":"2024","unstructured":"Sakowski SA, Koubek EJ, Chen KS et al (2024) Role of the exposome in neurodegenerative disease: recent insights and future directions. Ann Neurol 95:635\u2013652. https:\/\/doi.org\/10.1002\/ana.26897","journal-title":"Ann Neurol"},{"key":"10929_CR21","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL et al (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol 18:1091\u20131102. https:\/\/doi.org\/10.1016\/S1474-4422(19)30320-5","journal-title":"Lancet Neurol"},{"key":"10929_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00544-7","volume":"9","author":"J-M Taymans","year":"2023","unstructured":"Taymans J-M, Fell M, Greenamyre T et al (2023) Perspective on the current state of the LRRK2 field. NPJ Parkinsons Dis 9:104. https:\/\/doi.org\/10.1038\/s41531-023-00544-7","journal-title":"NPJ Parkinsons Dis"},{"key":"10929_CR23","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/cells11081261","volume":"11","author":"L Smith","year":"2022","unstructured":"Smith L, Schapira AHV (2022) GBA variants and Parkinson disease: mechanisms and treatments. Cells 11:1261. https:\/\/doi.org\/10.3390\/cells11081261","journal-title":"Cells"},{"key":"10929_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ane.12563","volume":"134","author":"K Kalinderi","year":"2016","unstructured":"Kalinderi K, Bostantjopoulou S, Fidani L (2016) The genetic background of Parkinson\u2019s disease: current progress and future prospects. Acta Neurol Scand 134:314\u2013326. https:\/\/doi.org\/10.1111\/ane.12563","journal-title":"Acta Neurol Scand"},{"key":"10929_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ana.10795","volume":"55","author":"JJ Zarranz","year":"2004","unstructured":"Zarranz JJ, Alegre J, G\u00f3mez-Esteban JC et al (2004) The new mutation, E46K, of \u03b1-synuclein causes parkinson and lewy body dementia. Ann Neurol 55:164\u2013173. https:\/\/doi.org\/10.1002\/ana.10795","journal-title":"Ann Neurol"},{"key":"10929_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13024-015-0038-3","volume":"10","author":"AP Kiely","year":"2015","unstructured":"Kiely AP, Ling H, Asi YT et al (2015) Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Mol Neurodegener 10:41. https:\/\/doi.org\/10.1186\/s13024-015-0038-3","journal-title":"Mol Neurodegener"},{"key":"10929_CR27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1212\/01.wnl.0000254458.17630.c5","volume":"68","author":"J Fuchs","year":"2007","unstructured":"Fuchs J, Nilsson C, Kachergus J et al (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68:916\u2013922. https:\/\/doi.org\/10.1212\/01.wnl.0000254458.17630.c5","journal-title":"Neurology"},{"key":"10929_CR28","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"C Pais\u00e1n-Ru\u0131\u0301z","year":"2004","unstructured":"Pais\u00e1n-Ru\u0131\u0301z C, Jain S, Evans EW et al (2004) Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson\u2019s Disease. Neuron 44:595\u2013600. https:\/\/doi.org\/10.1016\/j.neuron.2004.10.023","journal-title":"Neuron"},{"key":"10929_CR29","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ajhg.2011.06.008","volume":"89","author":"A Zimprich","year":"2011","unstructured":"Zimprich A, Benet-Pag\u00e8s A, Struhal W et al (2011) A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 89:168\u2013175. https:\/\/doi.org\/10.1016\/j.ajhg.2011.06.008","journal-title":"Am J Hum Genet"},{"key":"10929_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/33416","volume":"392","author":"T Kitada","year":"1998","unstructured":"Kitada T, Asakawa S, Hattori N et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605\u2013608. https:\/\/doi.org\/10.1038\/33416","journal-title":"Nature"},{"key":"10929_CR31","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.1096284","volume":"304","author":"EM Valente","year":"2004","unstructured":"Valente EM, Abou-Sleiman PM, Caputo V et al (2004) Hereditary early-onset Parkinson\u2019s disease caused by mutations in PINK1. Science 304:1158\u20131160. https:\/\/doi.org\/10.1126\/science.1096284","journal-title":"Science"},{"key":"10929_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/science.1077209","volume":"299","author":"V Bonifati","year":"2003","unstructured":"Bonifati V, Rizzu P, Van Baren MJ et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256\u2013259. https:\/\/doi.org\/10.1126\/science.1077209","journal-title":"Science"},{"key":"10929_CR33","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med 361:1651\u20131661. https:\/\/doi.org\/10.1056\/NEJMoa0901281","journal-title":"N Engl J Med"},{"key":"10929_CR34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/BF03208881","volume":"51","author":"KS Wang","year":"2010","unstructured":"Wang KS, Mullersman JE, Liu XF (2010) Family-based association analysis of theMAPT gene in Parkinson. J Appl Genet 51:509\u2013514. https:\/\/doi.org\/10.1007\/BF03208881","journal-title":"J Appl Genet"},{"key":"10929_CR35","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/ng1884","volume":"38","author":"A Ramirez","year":"2006","unstructured":"Ramirez A, Heimbach A, Gr\u00fcndemann J et al (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38:1184\u20131191. https:\/\/doi.org\/10.1038\/ng1884","journal-title":"Nat Genet"},{"key":"10929_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20017","volume":"55","author":"DM Maraganore","year":"2004","unstructured":"Maraganore DM, Lesnick TG, Elbaz A et al (2004) UCHL1 is a Parkinson\u2019s disease susceptibility gene. Ann Neurol 55:512\u2013521. https:\/\/doi.org\/10.1002\/ana.20017","journal-title":"Ann Neurol"},{"key":"10929_CR37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(10)62345-8","volume":"377","author":"MA Nalls","year":"2011","unstructured":"International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V et al (2011) Imputation of sequence variants for identification of genetic risks for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet 377:641\u2013649. https:\/\/doi.org\/10.1016\/S0140-6736(10)62345-8","journal-title":"Lancet"},{"key":"10929_CR38","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ng.485","volume":"41","author":"W Satake","year":"2009","unstructured":"Satake W, Nakabayashi Y, Mizuta I et al (2009) Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson\u2019s disease. Nat Genet 41:1303\u20131307. https:\/\/doi.org\/10.1038\/ng.485","journal-title":"Nat Genet"},{"key":"10929_CR39","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB (2020) The genetic architecture of Parkinson\u2019s disease. Lancet Neurol 19:170\u2013178. https:\/\/doi.org\/10.1016\/S1474-4422(19)30287-X","journal-title":"Lancet Neurol"},{"key":"10929_CR40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ana.410440312","volume":"44","author":"M Hirano","year":"1998","unstructured":"Hirano M, Yanagihara T, Ueno S (1998) Dominant negative effect of GTP cyclohydrolase I mutations in dopa-responsive hereditary progressive dystonia. Ann Neurol 44:365\u2013371. https:\/\/doi.org\/10.1002\/ana.410440312","journal-title":"Ann Neurol"},{"key":"10929_CR41","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/ng.642","volume":"42","author":"TH Hamza","year":"2010","unstructured":"Hamza TH, Zabetian CP, Tenesa A et al (2010) Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson\u2019s disease. Nat Genet 42:781\u2013785. https:\/\/doi.org\/10.1038\/ng.642","journal-title":"Nat Genet"},{"key":"10929_CR42","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ajhg.2011.08.009","volume":"89","author":"M-C Chartier-Harlin","year":"2011","unstructured":"Chartier-Harlin M-C, Dachsel JC, Vilari\u00f1o-G\u00fcell C et al (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 89:398\u2013406. https:\/\/doi.org\/10.1016\/j.ajhg.2011.08.009","journal-title":"Am J Hum Genet"},{"key":"10929_CR43","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.neurobiolaging.2010.05.009","volume":"33","author":"C Pais\u00e1n-Ruiz","year":"2012","unstructured":"Pais\u00e1n-Ruiz C, Li A, Schneider SA et al (2012) Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations. Neurobiol Aging 33:814\u2013823. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2010.05.009","journal-title":"Neurobiol Aging"},{"key":"10929_CR44","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1093\/brain\/awv082","volume":"138","author":"M Zhang","year":"2015","unstructured":"Zhang M, Xi Z, Zinman L et al (2015) Mutation analysis of CHCHD10 in different neurodegenerative diseases. Brain 138:e380\u2013e380. https:\/\/doi.org\/10.1093\/brain\/awv082","journal-title":"Brain"},{"key":"10929_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/epigenomes7010005","volume":"7","author":"EYu Fedotova","year":"2023","unstructured":"Fedotova EYu, Iakovenko EV, Abramycheva NYu, Illarioshkin SN (2023) SNCA gene methylation in Parkinson\u2019s disease and multiple system atrophy. Epigenomes 7:5. https:\/\/doi.org\/10.3390\/epigenomes7010005","journal-title":"Epigenomes"},{"key":"10929_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/mds.26073","volume":"30","author":"L Pihlstr\u00f8m","year":"2015","unstructured":"Pihlstr\u00f8m L, Berge V, Rengmark A, Toft M (2015) Parkinson\u2019s disease correlates with promoter methylation in the \u03b1-synuclein gene. Mov Disord 30:577\u2013580. https:\/\/doi.org\/10.1002\/mds.26073","journal-title":"Mov Disord"},{"key":"10929_CR47","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/01616412.2017.1368141","volume":"39","author":"IE Eryilmaz","year":"2017","unstructured":"Eryilmaz IE, Cecener G, Erer S et al (2017) Epigenetic approach to early-onset Parkinson\u2019s disease: low methylation status of SNCA and PARK2 promoter regions. Neurol Res 39:965\u2013972. https:\/\/doi.org\/10.1080\/01616412.2017.1368141","journal-title":"Neurol Res"},{"key":"10929_CR48","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/mds.27864","volume":"34","author":"S Bandres-Ciga","year":"2019","unstructured":"Bandres-Ciga S, Ahmed S, Sabir MS et al (2019) The genetic architecture of Parkinson disease in Spain: characterizing population-specific risk, differential haplotype structures, and providing etiologic insight. Mov Disord 34:1851\u20131863. https:\/\/doi.org\/10.1002\/mds.27864","journal-title":"Mov Disord"},{"key":"10929_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134087","volume":"10","author":"X Su","year":"2015","unstructured":"Su X, Chu Y, Kordower JH et al (2015) PGC-1\u03b1 promoter methylation in Parkinson\u2019s disease. PLoS ONE 10:e0134087. https:\/\/doi.org\/10.1371\/journal.pone.0134087","journal-title":"PLoS ONE"},{"key":"10929_CR50","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/mds.25784","volume":"29","author":"KG Coupland","year":"2014","unstructured":"Coupland KG, Mellick GD, Silburn PA et al (2014) DNA methylation of the MAPT gene in Parkinson\u2019s disease cohorts and modulation by vitamin E in vitro. Mov Disord 29:1606\u20131614. https:\/\/doi.org\/10.1002\/mds.25784","journal-title":"Mov Disord"},{"key":"10929_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8935-5-6","volume":"5","author":"JGD Prendergast","year":"2012","unstructured":"Prendergast JGD, Tong P, Hay DC et al (2012) A genome-wide screen in human embryonic stem cells reveals novel sites of allele-specific histone modification associated with known disease loci. Epigenetics Chromatin 5:6. https:\/\/doi.org\/10.1186\/1756-8935-5-6","journal-title":"Epigenetics Chromatin"},{"key":"10929_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00450-7","volume":"16","author":"L Toker","year":"2021","unstructured":"Toker L, Tran GT, Sundaresan J et al (2021) Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson\u2019s disease brain. Mol Neurodegener 16:31. https:\/\/doi.org\/10.1186\/s13024-021-00450-7","journal-title":"Mol Neurodegener"},{"key":"10929_CR53","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1093\/hmg\/ddr210","volume":"20","author":"E Mi\u00f1ones-Moyano","year":"2011","unstructured":"Mi\u00f1ones-Moyano E, Porta S, Escaram\u00eds G et al (2011) Microrna profiling of Parkinson\u2019s disease brains identifies early downregulation of miR-34b\/c which modulate mitochondrial function. Hum Mol Genet 20:3067\u20133078. https:\/\/doi.org\/10.1093\/hmg\/ddr210","journal-title":"Hum Mol Genet"},{"key":"10929_CR54","first-page":"11192","volume":"24","author":"L-G Dong","year":"2020","unstructured":"Dong L-G, Lu F-F, Zu J et al (2020) MiR-133b inhibits MPP+-induced apoptosis in Parkinson\u2019s disease model by inhibiting the ERK1\/2 signaling pathway. Eur Rev Med Pharmacol Sci 24:11192\u201311198","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10929_CR55","doi-asserted-by":"publisher","first-page":"12726","DOI":"10.1074\/jbc.M109.086827","volume":"285","author":"E Doxakis","year":"2010","unstructured":"Doxakis E (2010) Post-transcriptional regulation of \u03b1-Synuclein expression by mir-7 and mir-153. J Biol Chem 285:12726\u201312734. https:\/\/doi.org\/10.1074\/jbc.M109.086827","journal-title":"J Biol Chem"},{"key":"10929_CR56","doi-asserted-by":"publisher","first-page":"13052","DOI":"10.1073\/pnas.0906277106","volume":"106","author":"E Junn","year":"2009","unstructured":"Junn E, Lee K-W, Jeong BS et al (2009) Repression of \u03b1-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci 106:13052\u201313057. https:\/\/doi.org\/10.1073\/pnas.0906277106","journal-title":"Proc Natl Acad Sci"},{"key":"10929_CR57","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/jnr.23377","volume":"92","author":"T Botta-Orfila","year":"2014","unstructured":"Botta-Orfila T, Morat\u00f3 X, Compta Y et al (2014) Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson\u2019s disease. J Neurosci Res 92:1071\u20131077. https:\/\/doi.org\/10.1002\/jnr.23377","journal-title":"J Neurosci Res"},{"key":"10929_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2013.00010","author":"L Soreq","year":"2013","unstructured":"Soreq L, Salomonis N, Bronstein M et al (2013) Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2013.00010","journal-title":"Front Mol Neurosci"},{"key":"10929_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104515","volume":"150","author":"E Angelopoulou","year":"2019","unstructured":"Angelopoulou E, Paudel YN, Piperi C (2019) MiR-124 and Parkinson\u2019s disease: a biomarker with therapeutic potential. Pharmacol Res 150:104515. https:\/\/doi.org\/10.1016\/j.phrs.2019.104515","journal-title":"Pharmacol Res"},{"key":"10929_CR60","doi-asserted-by":"publisher","first-page":"24449","DOI":"10.18632\/oncotarget.15511","volume":"8","author":"S Wang","year":"2017","unstructured":"Wang S, Zhang X, Guo Y et al (2017) The long noncoding RNA HOTAIR promotes Parkinson\u2019s disease by upregulating LRRK2 expression. Oncotarget 8:24449\u201324456. https:\/\/doi.org\/10.18632\/oncotarget.15511","journal-title":"Oncotarget"},{"key":"10929_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13115","volume":"19","author":"A Simchovitz","year":"2020","unstructured":"Simchovitz A, Hanan M, Yayon N et al (2020) A lncrna survey finds increases in neuroprotective LINC-PINT in Parkinson\u2019s disease substantia nigra. Aging Cell 19:e13115. https:\/\/doi.org\/10.1111\/acel.13115","journal-title":"Aging Cell"},{"key":"10929_CR62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13041-020-00656-8","volume":"13","author":"L-J Cai","year":"2020","unstructured":"Cai L-J, Tu L, Huang X-M et al (2020) LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson\u2019s disease. Mol Brain 13:130. https:\/\/doi.org\/10.1186\/s13041-020-00656-8","journal-title":"Mol Brain"},{"key":"10929_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.146672","volume":"1730","author":"FA Boros","year":"2020","unstructured":"Boros FA, Maszlag-T\u00f6r\u00f6k R, V\u00e9csei L, Kliv\u00e9nyi P (2020) Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson\u2019s disease. Brain Res 1730:146672. https:\/\/doi.org\/10.1016\/j.brainres.2020.146672","journal-title":"Brain Res"},{"key":"10929_CR64","doi-asserted-by":"publisher","first-page":"11223","DOI":"10.1096\/fj.201900830R","volume":"33","author":"A Simchovitz","year":"2019","unstructured":"Simchovitz A, Hanan M, Niederhoffer N et al (2019) NEAT1 is overexpressed in Parkinson\u2019s disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress. FASEB J 33:11223\u201311234. https:\/\/doi.org\/10.1096\/fj.201900830R","journal-title":"FASEB J"},{"key":"10929_CR65","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/aws055","volume":"135","author":"DS Goldstein","year":"2012","unstructured":"Goldstein DS, Holmes C, Sharabi Y (2012) Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson\u2019s disease and other synucleinopathies. Brain 135:1900\u20131913. https:\/\/doi.org\/10.1093\/brain\/aws055","journal-title":"Brain"},{"key":"10929_CR66","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2010.03246.x","volume":"18","author":"DS Goldstein","year":"2011","unstructured":"Goldstein DS, Sullivan P, Holmes C et al (2011) Catechols in post-mortem brain of patients with Parkinson disease: brain catechols in Parkinson disease. Eur J Neurol 18:703\u2013710. https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03246.x","journal-title":"Eur J Neurol"},{"key":"10929_CR67","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.nbd.2008.11.011","volume":"33","author":"C-M Chen","year":"2009","unstructured":"Chen C-M, Liu J-L, Wu Y-R et al (2009) Increased oxidative damage in peripheral blood correlates with severity of Parkinson\u2019s disease. Neurobiol Dis 33:429\u2013435. https:\/\/doi.org\/10.1016\/j.nbd.2008.11.011","journal-title":"Neurobiol Dis"},{"key":"10929_CR68","doi-asserted-by":"publisher","first-page":"24384","DOI":"10.1038\/s41598-021-03700-2","volume":"11","author":"LC Jellen","year":"2021","unstructured":"Jellen LC, Lewis MM, Du G et al (2021) Low plasma serotonin linked to higher nigral iron in Parkinson\u2019s disease. Sci Rep 11:24384. https:\/\/doi.org\/10.1038\/s41598-021-03700-2","journal-title":"Sci Rep"},{"key":"10929_CR69","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1468-1331.2007.01727.x","volume":"14","author":"M Guttman","year":"2007","unstructured":"Guttman M, Boileau I, Warsh J et al (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson\u2019s disease. Eur J Neurol 14:523\u2013528. https:\/\/doi.org\/10.1111\/j.1468-1331.2007.01727.x","journal-title":"Eur J Neurol"},{"key":"10929_CR70","first-page":"129","volume":"13","author":"J Sanyal","year":"2009","unstructured":"Sanyal J, Bandyopadhyay SK, Banerjee TK et al (2009) Plasma levels of lipid peroxides in patients with Parkinson\u2019s disease. Eur Rev Med Pharmacol Sci 13:129\u2013132","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10929_CR71","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10072-016-2782-8","volume":"38","author":"B G\u00f6k\u00e7e \u00c7okal","year":"2017","unstructured":"G\u00f6k\u00e7e \u00c7okal B, Yurtda\u015f M, Keskin G\u00fcler S et al (2017) Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson\u2019s disease. Neurol Sci 38:425\u2013431. https:\/\/doi.org\/10.1007\/s10072-016-2782-8","journal-title":"Neurol Sci"},{"key":"10929_CR72","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/brain\/awm304","volume":"131","author":"M Bogdanov","year":"2008","unstructured":"Bogdanov M, Matson WR, Wang L et al (2008) Metabolomic profiling to develop blood biomarkers for Parkinson\u2019s disease. Brain 131:389\u2013396. https:\/\/doi.org\/10.1093\/brain\/awm304","journal-title":"Brain"},{"key":"10929_CR73","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1212\/01.WNL.0000154597.24838.6B","volume":"64","author":"S Sato","year":"2005","unstructured":"Sato S, Mizuno Y, Hattori N (2005) Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64:1081\u20131083. https:\/\/doi.org\/10.1212\/01.WNL.0000154597.24838.6B","journal-title":"Neurology"},{"key":"10929_CR74","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10072-020-04589-x","volume":"42","author":"J Bai","year":"2021","unstructured":"Bai J, Zheng Y, Yu Y (2021) Urinary kynurenine as a biomarker for Parkinson\u2019s disease. Neurol Sci 42:697\u2013703. https:\/\/doi.org\/10.1007\/s10072-020-04589-x","journal-title":"Neurol Sci"},{"key":"10929_CR75","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neulet.2009.10.062","volume":"468","author":"P Scalzo","year":"2010","unstructured":"Scalzo P, K\u00fcmmer A, Cardoso F, Teixeira AL (2010) Serum levels of interleukin-6 are elevated in patients with Parkinson\u2019s disease and correlate with physical performance. Neurosci Lett 468:56\u201358. https:\/\/doi.org\/10.1016\/j.neulet.2009.10.062","journal-title":"Neurosci Lett"},{"key":"10929_CR76","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"X-Y Qin","year":"2016","unstructured":"Qin X-Y, Zhang S-P, Cao C et al (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73:1316. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2742","journal-title":"JAMA Neurol"},{"key":"10929_CR77","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1038\/s41467-024-48961-3","volume":"15","author":"J H\u00e4llqvist","year":"2024","unstructured":"H\u00e4llqvist J, Bartl M, Dakna M et al (2024) Plasma proteomics identify biomarkers predicting Parkinson\u2019s disease up to 7 years before symptom onset. Nat Commun 15:4759. https:\/\/doi.org\/10.1038\/s41467-024-48961-3","journal-title":"Nat Commun"},{"key":"10929_CR78","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1073\/pnas.0837397100","volume":"100","author":"P Teismann","year":"2003","unstructured":"Teismann P, Tieu K, Choi D-K et al (2003) Cyclooxygenase-2 is instrumental in Parkinson\u2019s disease neurodegeneration. Proc Natl Acad Sci 100:5473\u20135478. https:\/\/doi.org\/10.1073\/pnas.0837397100","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"10929_CR79","doi-asserted-by":"publisher","first-page":"e1391","DOI":"10.1212\/WNL.0000000000011553","volume":"96","author":"J-H Park","year":"2021","unstructured":"Park J-H, Lee C, Nam MJ et al (2021) Association of high-density lipoprotein cholesterol variability and the risk of developing Parkinson disease. Neurology 96(10):e1391\u2013e1401. https:\/\/doi.org\/10.1212\/WNL.0000000000011553","journal-title":"Neurology"},{"key":"10929_CR80","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/mds.21290","volume":"22","author":"X Huang","year":"2007","unstructured":"Huang X, Chen H, Miller WC et al (2007) Lower low-density lipoprotein cholesterol levels are associated with Parkinson\u2019s disease. Mov Disord 22:377\u2013381. https:\/\/doi.org\/10.1002\/mds.21290","journal-title":"Mov Disord"},{"key":"10929_CR81","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12944-020-01284-w","volume":"19","author":"X Fu","year":"2020","unstructured":"Fu X, Wang Y, He X et al (2020) A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson\u2019s disease. Lipids Health Dis 19:97. https:\/\/doi.org\/10.1186\/s12944-020-01284-w","journal-title":"Lipids Health Dis"},{"key":"10929_CR82","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/cells11030395","volume":"11","author":"K-H Chang","year":"2022","unstructured":"Chang K-H, Cheng M-L, Tang H-Y et al (2022) Alterations of sphingolipid and phospholipid pathways and ornithine level in the plasma as biomarkers of Parkinson\u2019s disease. Cells 11:395. https:\/\/doi.org\/10.3390\/cells11030395","journal-title":"Cells"},{"key":"10929_CR83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025347118","volume":"118","author":"M Vos","year":"2021","unstructured":"Vos M, Dulovic-Mahlow M, Mandik F et al (2021) Ceramide accumulation induces mitophagy and impairs \u03b2-oxidation in PINK1 deficiency. Proc Natl Acad Sci 118:e2025347118. https:\/\/doi.org\/10.1073\/pnas.2025347118","journal-title":"Proc Natl Acad Sci"},{"key":"10929_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168000","volume":"435","author":"M Vos","year":"2023","unstructured":"Vos M, Klein C, Hicks AA (2023) Role of ceramides and sphingolipids in Parkinson\u2019s disease. J Mol Biol 435:168000. https:\/\/doi.org\/10.1016\/j.jmb.2023.168000","journal-title":"J Mol Biol"},{"key":"10929_CR85","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cca.2020.08.005","volume":"510","author":"S Kumari","year":"2020","unstructured":"Kumari S, Kumaran SS, Goyal V et al (2020) Identification of potential urine biomarkers in idiopathic parkinson\u2019s disease using NMR. Clin Chim Acta 510:442\u2013449. https:\/\/doi.org\/10.1016\/j.cca.2020.08.005","journal-title":"Clin Chim Acta"},{"key":"10929_CR86","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/pr500807t","volume":"14","author":"H Luan","year":"2015","unstructured":"Luan H, Liu L-F, Meng N et al (2015) LC\u2013MS-based urinary metabolite signatures in idiopathic Parkinson\u2019s disease. J Proteome Res 14:467\u2013478. https:\/\/doi.org\/10.1021\/pr500807t","journal-title":"J Proteome Res"},{"key":"10929_CR87","doi-asserted-by":"publisher","first-page":"13888","DOI":"10.1038\/srep13888","volume":"5","author":"H Luan","year":"2015","unstructured":"Luan H, Liu L-F, Tang Z et al (2015) Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson\u2019s disease. Sci Rep 5:13888. https:\/\/doi.org\/10.1038\/srep13888","journal-title":"Sci Rep"},{"key":"10929_CR88","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1080\/13607863.2020.1839860","volume":"25","author":"G Santangelo","year":"2021","unstructured":"Santangelo G, Raimo S, Erro R et al (2021) Vitamin D as a possible biomarker of mild cognitive impairment in parkinsonians. Aging Ment Health 25:1998\u20132002. https:\/\/doi.org\/10.1080\/13607863.2020.1839860","journal-title":"Aging Ment Health"},{"key":"10929_CR89","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ibneur.2023.02.006","volume":"16","author":"M Xia","year":"2024","unstructured":"Xia M, Zhou Q (2024) Correlation between 25-hydroxy-vitamin D and Parkinson\u2019s disease. IBRO Neurosci Rep 16:162\u2013167. https:\/\/doi.org\/10.1016\/j.ibneur.2023.02.006","journal-title":"IBRO Neurosci Rep"},{"key":"10929_CR90","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.parkreldis.2017.02.010","volume":"37","author":"M Picillo","year":"2017","unstructured":"Picillo M, Santangelo G, Erro R et al (2017) Association between dopaminergic dysfunction and anxiety in de novo Parkinson\u2019s disease. Parkinsonism Relat Disord 37:106\u2013110. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.02.010","journal-title":"Parkinsonism Relat Disord"},{"key":"10929_CR91","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/diagnostics13040693","volume":"13","author":"J Joo","year":"2023","unstructured":"Joo J, Jeong J, Park HJ (2023) Blood biomarkers in patients with Parkinson\u2019s disease: a review in context of anesthetic care. Diagnostics 13:693. https:\/\/doi.org\/10.3390\/diagnostics13040693","journal-title":"Diagnostics"},{"key":"10929_CR92","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cells8010027","volume":"8","author":"H Xicoy","year":"2019","unstructured":"Xicoy H, Wieringa B, Martens GJM (2019) The role of lipids in Parkinson\u2019s disease. Cells 8:27. https:\/\/doi.org\/10.3390\/cells8010027","journal-title":"Cells"},{"key":"10929_CR93","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao Y, Li T, Liu Z et al (2021) Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol Neurodegener 16:4. https:\/\/doi.org\/10.1186\/s13024-021-00425-8","journal-title":"Mol Neurodegener"},{"key":"10929_CR94","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/jnc.14809","volume":"150","author":"M Fayyad","year":"2019","unstructured":"Fayyad M, Salim S, Majbour N et al (2019) Parkinson\u2019s disease biomarkers based on \u03b1-synuclein. J Neurochem 150:626\u2013636. https:\/\/doi.org\/10.1111\/jnc.14809","journal-title":"J Neurochem"},{"key":"10929_CR95","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/mds.23344","volume":"26","author":"MG Cers\u00f3simo","year":"2011","unstructured":"Cers\u00f3simo MG, Perandones C, Micheli FE et al (2011) Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson\u2019s disease patients. Mov Disord 26:188\u2013190. https:\/\/doi.org\/10.1002\/mds.23344","journal-title":"Mov Disord"},{"key":"10929_CR96","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L (2012) Synuclein in Parkinson\u2019s Disease. Cold Spring Harb Perspect Med 2:a009399\u2013a009399. https:\/\/doi.org\/10.1101\/cshperspect.a009399","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10929_CR97","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/mds.28976","volume":"37","author":"M Luan","year":"2022","unstructured":"Luan M, Sun Y, Chen J et al (2022) Diagnostic value of salivary real-time quaking-induced conversion in Parkinson\u2019s disease and multiple system atrophy. Mov Disord 37:1059\u20131063. https:\/\/doi.org\/10.1002\/mds.28976","journal-title":"Mov Disord"},{"key":"10929_CR98","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00401-023-02663-0","volume":"147","author":"GM Bentivenga","year":"2024","unstructured":"Bentivenga GM, Mammana A, Baiardi S et al (2024) Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol (Berl) 147:18. https:\/\/doi.org\/10.1007\/s00401-023-02663-0","journal-title":"Acta Neuropathol (Berl)"},{"key":"10929_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105807","volume":"117","author":"B Fernandes Gomes","year":"2023","unstructured":"Fernandes Gomes B, Farris CM, Ma Y et al (2023) \u03b1-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders. Parkinsonism Relat Disord 117:105807. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105807","journal-title":"Parkinsonism Relat Disord"},{"key":"10929_CR100","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.26453","volume":"92","author":"MR Arnold","year":"2022","unstructured":"Arnold MR, Coughlin DG, Brumbach BH et al (2022) \u03b1-Synuclein seed amplification in CSF and brain from patients with different brain distributions of pathological \u03b1-synuclein in the context of co-pathology and Non-LBD diagnoses. Ann Neurol 92:650\u2013662. https:\/\/doi.org\/10.1002\/ana.26453","journal-title":"Ann Neurol"},{"key":"10929_CR101","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41531-023-00473-5","volume":"9","author":"R Liguori","year":"2023","unstructured":"Liguori R, Donadio V, Wang Z et al (2023) A comparative blind study between skin biopsy and seed amplification assay to disclose pathological \u03b1-synuclein in RBD. Npj Park Dis 9:34. https:\/\/doi.org\/10.1038\/s41531-023-00473-5","journal-title":"Npj Park Dis"},{"key":"10929_CR102","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/mds.29329","volume":"38","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Weber S, Farris CM et al (2023) Accurate detection of \u03b1-synuclein seeds in cerebrospinal fluid from isolated rapid eye movement sleep behavior disorder and patients with Parkinson\u2019s disease in the DeNovo Parkinson (DeNoPa) cohort. Mov Disord 38:567\u2013578. https:\/\/doi.org\/10.1002\/mds.29329","journal-title":"Mov Disord"},{"key":"10929_CR103","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41531-023-00519-8","volume":"9","author":"A Kuzkina","year":"2023","unstructured":"Kuzkina A, R\u00f6\u00dfle J, Seger A et al (2023) Combining skin and olfactory \u03b1-synuclein seed amplification assays (SAA)\u2014towards biomarker-driven phenotyping in synucleinopathies. Npj Park Dis 9:79. https:\/\/doi.org\/10.1038\/s41531-023-00519-8","journal-title":"Npj Park Dis"},{"key":"10929_CR104","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-1-4939-8820-4_2","volume-title":"Protein Misfolding Diseases","author":"E Saijo","year":"2019","unstructured":"Saijo E, Groveman BR, Kraus A et al (2019) Ultrasensitive RT-QuIC seed amplification assays for disease-associated tau, \u03b1-synuclein, and prion aggregates. In: Gomes CM (ed) Protein Misfolding Diseases. Springer, New York, New York, NY, pp 19\u201337"},{"key":"10929_CR105","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13024-023-00613-8","volume":"18","author":"G Bellomo","year":"2023","unstructured":"Bellomo G, Paciotti S, Concha-Marambio L et al (2023) Cerebrospinal fluid lipoproteins inhibit \u03b1-synuclein aggregation by interacting with oligomeric species in seed amplification assays. Mol Neurodegener 18:20. https:\/\/doi.org\/10.1186\/s13024-023-00613-8","journal-title":"Mol Neurodegener"},{"key":"10929_CR106","unstructured":"Telano LN, Baker S (2025) Physiology, Cerebral Spinal Fluid. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"10929_CR107","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s12276-024-01186-2","volume":"56","author":"J Lim","year":"2024","unstructured":"Lim J, Park C, Kim M et al (2024) Advances in single-cell omics and multiomics for high-resolution molecular profiling. Exp Mol Med 56:515\u2013526. https:\/\/doi.org\/10.1038\/s12276-024-01186-2","journal-title":"Exp Mol Med"},{"key":"10929_CR108","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fnana.2014.00155","volume":"8","author":"J Blesa","year":"2014","unstructured":"Blesa J, Przedborski S (2014) Parkinson\u00e2\u20acTMs disease: animal models and dopaminergic cell vulnerability. Front Neuroanat 8:155. https:\/\/doi.org\/10.3389\/fnana.2014.00155","journal-title":"Front Neuroanat"},{"key":"10929_CR109","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fncel.2018.00114","volume":"12","author":"H Solleiro-Villavicencio","year":"2018","unstructured":"Solleiro-Villavicencio H, Rivas-Arancibia S (2018) Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4+T Cells in neurodegenerative diseases. Front Cell Neurosci 12:114. https:\/\/doi.org\/10.3389\/fncel.2018.00114","journal-title":"Front Cell Neurosci"},{"key":"10929_CR110","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0002-9440(10)65396-5","volume":"154","author":"J Zhang","year":"1999","unstructured":"Zhang J, Perry G, Smith MA et al (1999) Parkinson\u2019s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154:1423\u20131429. https:\/\/doi.org\/10.1016\/S0002-9440(10)65396-5","journal-title":"Am J Pathol"},{"key":"10929_CR111","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13031","volume":"18","author":"BG Trist","year":"2019","unstructured":"Trist BG, Hare DJ, Double KL (2019) Oxidative stress in the aging substantia nigra and the etiology of Parkinson\u2019s disease. Aging Cell 18:e13031. https:\/\/doi.org\/10.1111\/acel.13031","journal-title":"Aging Cell"},{"key":"10929_CR112","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/hmg\/ddm080","volume":"16","author":"C Iaccarino","year":"2007","unstructured":"Iaccarino C, Crosio C, Vitale C et al (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16:1319\u20131326. https:\/\/doi.org\/10.1093\/hmg\/ddm080","journal-title":"Hum Mol Genet"},{"key":"10929_CR113","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.parkreldis.2015.07.021","volume":"21","author":"JM Masters","year":"2015","unstructured":"Masters JM, Noyce AJ, Warner TT et al (2015) Elevated salivary protein in Parkinson\u2019s disease and salivary DJ-1 as a potential marker of disease severity. Parkinsonism Relat Disord 21:1251\u20131255. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.07.021","journal-title":"Parkinsonism Relat Disord"},{"key":"10929_CR114","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3389\/fnagi.2020.00210","volume":"12","author":"Y Chen","year":"2020","unstructured":"Chen Y, Zheng J, Su L et al (2020) Increased salivary microRNAs that regulate DJ-1 gene expression as potential markers for Parkinson\u2019s disease. Front Aging Neurosci 12:210. https:\/\/doi.org\/10.3389\/fnagi.2020.00210","journal-title":"Front Aging Neurosci"},{"key":"10929_CR115","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41593-022-01140-3","volume":"25","author":"ML Choi","year":"2022","unstructured":"Choi ML, Chappard A, Singh BP et al (2022) Pathological structural conversion of \u03b1-synuclein at the mitochondria induces neuronal toxicity. Nat Neurosci 25:1134\u20131148. https:\/\/doi.org\/10.1038\/s41593-022-01140-3","journal-title":"Nat Neurosci"},{"key":"10929_CR116","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1089\/ars.2015.6343","volume":"24","author":"E Deas","year":"2016","unstructured":"Deas E, Cremades N, Angelova PR et al (2016) Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson\u2019s disease. Antioxid Redox Signal 24:376\u2013391. https:\/\/doi.org\/10.1089\/ars.2015.6343","journal-title":"Antioxid Redox Signal"},{"key":"10929_CR117","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ajme.2017.09.001","volume":"54","author":"OM Ighodaro","year":"2018","unstructured":"Ighodaro OM, Akinloye OA (2018) First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. Alex J Med 54:287\u2013293. https:\/\/doi.org\/10.1016\/j.ajme.2017.09.001","journal-title":"Alex J Med"},{"key":"10929_CR118","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jnc.13607","volume":"139","author":"DJ DiSabato","year":"2016","unstructured":"DiSabato DJ, Quan N, Godbout JP (2016) Neuroinflammation: the devil is in the details. J Neurochem 139:136\u2013153. https:\/\/doi.org\/10.1111\/jnc.13607","journal-title":"J Neurochem"},{"key":"10929_CR119","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells9071687","volume":"9","author":"MI Pajares","year":"2020","unstructured":"Pajares MI, Rojo A, Manda G et al (2020) Inflammation in Parkinson\u2019s disease: mechanisms and therapeutic implications. Cells 9:1687. https:\/\/doi.org\/10.3390\/cells9071687","journal-title":"Cells"},{"key":"10929_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JPD-140491","volume":"5","author":"HE Allen Reish","year":"2015","unstructured":"Allen Reish HE, Standaert DG (2015) Role of \u03b1-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Park Dis 5:1\u201319. https:\/\/doi.org\/10.3233\/JPD-140491","journal-title":"J Park Dis"},{"key":"10929_CR121","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.toxlet.2016.11.002","volume":"265","author":"Q-S Zhang","year":"2017","unstructured":"Zhang Q-S, Heng Y, Yuan Y-H, Chen N-H (2017) Pathological \u03b1-synuclein exacerbates the progression of Parkinson\u2019s disease through microglial activation. Toxicol Lett 265:30\u201337. https:\/\/doi.org\/10.1016\/j.toxlet.2016.11.002","journal-title":"Toxicol Lett"},{"key":"10929_CR122","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.conb.2021.09.001","volume":"72","author":"E Nachman","year":"2022","unstructured":"Nachman E, Verstreken P (2022) Synaptic proteostasis in Parkinson\u2019s disease. Curr Opin Neurobiol 72:72\u201379. https:\/\/doi.org\/10.1016\/j.conb.2021.09.001","journal-title":"Curr Opin Neurobiol"},{"key":"10929_CR123","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41467-024-44732-2","volume":"15","author":"G Morrone Parfitt","year":"2024","unstructured":"Morrone Parfitt G, Coccia E, Goldman C et al (2024) Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson\u2019s disease model. Nat Commun 15:447. https:\/\/doi.org\/10.1038\/s41467-024-44732-2","journal-title":"Nat Commun"},{"key":"10929_CR124","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40035-019-0145-0","volume":"8","author":"ZD Zhou","year":"2019","unstructured":"Zhou ZD, Selvaratnam T, Lee JCT et al (2019) Molecular targets for modulating the protein translation vital to proteostasis and neuron degeneration in Parkinson\u2019s disease. Transl Neurodegener 8:6. https:\/\/doi.org\/10.1186\/s40035-019-0145-0","journal-title":"Transl Neurodegener"},{"key":"10929_CR125","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nature10317","volume":"475","author":"FU Hartl","year":"2011","unstructured":"Hartl FU, Bracher A, Hayer-Hartl M (2011) Molecular chaperones in protein folding and proteostasis. Nature 475:324\u2013332. https:\/\/doi.org\/10.1038\/nature10317","journal-title":"Nature"},{"key":"10929_CR126","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41531-023-00460-w","volume":"9","author":"D Flinkman","year":"2023","unstructured":"Flinkman D, Hong Y, Gnjatovic J et al (2023) Regulators of proteostasis are translationally repressed in fibroblasts from patients with sporadic and LRRK2-G2019S Parkinson\u2019s disease. Npj Park Dis 9:20. https:\/\/doi.org\/10.1038\/s41531-023-00460-w","journal-title":"Npj Park Dis"},{"key":"10929_CR127","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/diseases8020024","volume":"8","author":"N Joshi","year":"2020","unstructured":"Joshi N, Raveendran A, Nagotu S (2020) Chaperones and proteostasis: role in Parkinson\u2019s disease. Diseases 8:24. https:\/\/doi.org\/10.3390\/diseases8020024","journal-title":"Diseases"},{"key":"10929_CR128","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.neuron.2021.10.032","volume":"110","author":"I Stojkovska","year":"2022","unstructured":"Stojkovska I, Wani WY, Zunke F et al (2022) Rescue of \u03b1-synuclein aggregation in Parkinson\u2019s patient neurons by synergistic enhancement of ER proteostasis and protein trafficking. Neuron 110:436\u2013451. https:\/\/doi.org\/10.1016\/j.neuron.2021.10.032","journal-title":"Neuron"},{"key":"10929_CR129","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1002\/ana.410440716","volume":"44","author":"MF Beal","year":"1998","unstructured":"Beal MF (1998) Excitotoxicity and nitric oxide in parkinson\u2019s disease pathogenesis. Ann Neurol 44:S110\u2013S114. https:\/\/doi.org\/10.1002\/ana.410440716","journal-title":"Ann Neurol"},{"key":"10929_CR130","doi-asserted-by":"publisher","first-page":"50","DOI":"10.17116\/jnevro201811806250","volume":"118","author":"YS Mironova","year":"2018","unstructured":"Mironova YS, Zhukova IA, Zhukova NG et al (2018) Parkinson\u2019s disease and glutamate excitotoxicity. Zhurnal Nevrol Psikhiatrii Im SS Korsakova 118:50\u201354. https:\/\/doi.org\/10.17116\/jnevro201811806250","journal-title":"Zhurnal Nevrol Psikhiatrii Im SS Korsakova"},{"key":"10929_CR131","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci 144:151\u2013164. https:\/\/doi.org\/10.1016\/j.jphs.2020.07.011","journal-title":"J Pharmacol Sci"},{"key":"10929_CR132","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1007\/s12035-024-04644-0","volume":"62","author":"S Das","year":"2025","unstructured":"Das S, Mccloskey K, Nepal B, Kortagere S (2025) EAAT2 activation regulates glutamate excitotoxicity and reduces impulsivity in a rodent model of Parkinson\u2019s disease. Mol Neurobiol 62:5787\u20135803. https:\/\/doi.org\/10.1007\/s12035-024-04644-0","journal-title":"Mol Neurobiol"},{"key":"10929_CR133","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2015.03.033","volume":"207","author":"MJ Haney","year":"2015","unstructured":"Haney MJ, Klyachko NL, Zhao Y et al (2015) Exosomes as drug delivery vehicles for Parkinson\u2019s disease therapy. J Controlled Release 207:18\u201330. https:\/\/doi.org\/10.1016\/j.jconrel.2015.03.033","journal-title":"J Controlled Release"},{"key":"10929_CR134","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jconrel.2018.08.035","volume":"287","author":"M Qu","year":"2018","unstructured":"Qu M, Lin Q, Huang L et al (2018) Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson\u2019s disease. J Controlled Release 287:156\u2013166. https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.035","journal-title":"J Controlled Release"},{"key":"10929_CR135","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/jnc.15288","volume":"157","author":"JR Pinnell","year":"2021","unstructured":"Pinnell JR, Cui M, Tieu K (2021) Exosomes in Parkinson disease. J Neurochem 157:413\u2013428. https:\/\/doi.org\/10.1111\/jnc.15288","journal-title":"J Neurochem"},{"key":"10929_CR136","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41531-024-00791-2","volume":"10","author":"N Shaheen","year":"2024","unstructured":"Shaheen N, Shaheen A, Osama M et al (2024) MicroRNAs regulation in Parkinson\u2019s disease, and their potential role as diagnostic and therapeutic targets. Npj Park Dis 10:186. https:\/\/doi.org\/10.1038\/s41531-024-00791-2","journal-title":"Npj Park Dis"},{"key":"10929_CR137","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.26355\/eurrev_201808_15727","volume":"22","author":"Y-F Yao","year":"2018","unstructured":"Yao Y-F, Qu M-W, Li G-C et al (2018) Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson\u2019s disease. Eur Rev Med Pharmacol Sci 22:5278\u20135283. https:\/\/doi.org\/10.26355\/eurrev_201808_15727","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10929_CR138","doi-asserted-by":"publisher","first-page":"1216905","DOI":"10.3389\/fnagi.2023.1216905","volume":"15","author":"Z Chen","year":"2023","unstructured":"Chen Z, Pan C, Ruan X et al (2023) Evaluation of ferritin and TfR level in plasma neural-derived exosomes as potential markers of Parkinson\u2019s disease. Front Aging Neurosci 15:1216905. https:\/\/doi.org\/10.3389\/fnagi.2023.1216905","journal-title":"Front Aging Neurosci"},{"key":"10929_CR139","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1002\/mds.28591","volume":"36","author":"C Jiang","year":"2021","unstructured":"Jiang C, Hopfner F, Berg D et al (2021) Validation of \u03b1-synuclein in L1CAM\u2014immunocaptured exosomes as a biomarker for the stratification of parkinsonian syndromes. Mov Disord 36:2663\u20132669. https:\/\/doi.org\/10.1002\/mds.28591","journal-title":"Mov Disord"},{"key":"10929_CR140","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jalz.2016.04.003","volume":"12","author":"M Shi","year":"2016","unstructured":"Shi M, Kovac A, Korff A et al (2016) CNS tau efflux via exosomes is likely increased in Parkinson\u2019s disease but not in Alzheimer\u2019s disease. Alzheimers Dement 12:1125\u20131131. https:\/\/doi.org\/10.1016\/j.jalz.2016.04.003","journal-title":"Alzheimers Dement"},{"key":"10929_CR141","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy075","author":"VE Papadopoulos","year":"2018","unstructured":"Papadopoulos VE, Nikolopoulou G, Antoniadou I et al (2018) Modulation of \u03b2-glucocerebrosidase increases \u03b1-synuclein secretion and exosome release in mouse models of Parkinson\u2019s disease. Hum Mol Genet. https:\/\/doi.org\/10.1093\/hmg\/ddy075","journal-title":"Hum Mol Genet"},{"key":"10929_CR142","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","volume":"91","author":"C Jiang","year":"2020","unstructured":"Jiang C, Hopfner F, Katsikoudi A et al (2020) Serum neuronal exosomes predict and differentiate Parkinson\u2019s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry 91:720\u2013729. https:\/\/doi.org\/10.1136\/jnnp-2019-322588","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10929_CR143","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.3390\/ijms21197181","volume":"21","author":"C Lenzi","year":"2020","unstructured":"Lenzi C, Ramazzina I, Russo I et al (2020) The down-regulation of clusterin expression enhances the \u03b1synuclein aggregation process. Int J Mol Sci 21:7181. https:\/\/doi.org\/10.3390\/ijms21197181","journal-title":"Int J Mol Sci"},{"key":"10929_CR144","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuroscience.2018.09.017","volume":"392","author":"Y Kitamura","year":"2018","unstructured":"Kitamura Y, Kojima M, Kurosawa T et al (2018) Proteomic profiling of exosomal proteins for blood-based biomarkers in Parkinson\u2019s disease. Neuroscience 392:121\u2013128. https:\/\/doi.org\/10.1016\/j.neuroscience.2018.09.017","journal-title":"Neuroscience"},{"key":"10929_CR145","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neulet.2018.12.030","volume":"696","author":"Z Cao","year":"2019","unstructured":"Cao Z, Wu Y, Liu G et al (2019) \u03b1-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson\u2019s disease. Neurosci Lett 696:114\u2013120. https:\/\/doi.org\/10.1016\/j.neulet.2018.12.030","journal-title":"Neurosci Lett"},{"key":"10929_CR146","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3233\/JPD-201983","volume":"10","author":"D Nam","year":"2020","unstructured":"Nam D, Lee J-Y, Lee M et al (2020) Detection and assessment of \u03b1-synuclein oligomers in the urine of Parkinson\u2019s disease patients. J Park Dis 10:981\u2013991. https:\/\/doi.org\/10.3233\/JPD-201983","journal-title":"J Park Dis"},{"key":"10929_CR147","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.neuroscience.2021.06.033","volume":"469","author":"H Zheng","year":"2021","unstructured":"Zheng H, Xie Z, Zhang X et al (2021) Investigation of \u03b1-synuclein species in plasma exosomes and the oligomeric and phosphorylated \u03b1-synuclein as potential peripheral biomarker of Parkinson\u2019s disease. Neuroscience 469:79\u201390. https:\/\/doi.org\/10.1016\/j.neuroscience.2021.06.033","journal-title":"Neuroscience"},{"key":"10929_CR148","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","volume":"128","author":"M Shi","year":"2014","unstructured":"Shi M, Liu C, Cook TJ et al (2014) Plasma exosomal \u03b1-synuclein is likely CNS-derived and increased in Parkinson\u2019s disease. Acta Neuropathol (Berl) 128:639\u2013650. https:\/\/doi.org\/10.1007\/s00401-014-1314-y","journal-title":"Acta Neuropathol (Berl)"},{"key":"10929_CR149","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/brain\/awv346","volume":"139","author":"A Stuendl","year":"2016","unstructured":"Stuendl A, Kunadt M, Kruse N et al (2016) Induction of \u03b1-synuclein aggregate formation by CSF exosomes from patients with Parkinson\u2019s disease and dementia with Lewy bodies. Brain 139:481\u2013494. https:\/\/doi.org\/10.1093\/brain\/awv346","journal-title":"Brain"},{"key":"10929_CR150","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.3390\/diagnostics13132192","volume":"13","author":"D Anagnostou","year":"2023","unstructured":"Anagnostou D, Sfakianaki G, Melachroinou K et al (2023) Assessment of aggregated and exosome-associated \u03b1-synuclein in brain tissue and cerebrospinal fluid using specific immunoassays. Diagnostics 13:2192. https:\/\/doi.org\/10.3390\/diagnostics13132192","journal-title":"Diagnostics"},{"key":"10929_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/704678","volume":"2014","author":"DH Ho","year":"2014","unstructured":"Ho DH, Yi S, Seo H et al (2014) Increased DJ-1 in urine exosome of Korean males with Parkinson\u2019s disease. BioMed Res Int 2014:1\u20138. https:\/\/doi.org\/10.1155\/2014\/704678","journal-title":"BioMed Res Int"},{"key":"10929_CR152","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fnagi.2018.00438","volume":"10","author":"Z-H Zhao","year":"2019","unstructured":"Zhao Z-H, Chen Z-T, Zhou R-L et al (2019) Increased DJ-1 and \u03b1-synuclein in plasma neural-derived exosomes as potential markers for Parkinson\u2019s disease. Front Aging Neurosci 10:438. https:\/\/doi.org\/10.3389\/fnagi.2018.00438","journal-title":"Front Aging Neurosci"},{"key":"10929_CR153","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40478-017-0492-y","volume":"5","author":"S Wang","year":"2017","unstructured":"Wang S, Liu Z, Ye T et al (2017) Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathol Commun 5:86. https:\/\/doi.org\/10.1186\/s40478-017-0492-y","journal-title":"Acta Neuropathol Commun"},{"key":"10929_CR154","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017478","volume":"98","author":"R Jiang","year":"2019","unstructured":"Jiang R, Rong C, Ke R et al (2019) Differential proteomic analysis of serum exosomes reveals alterations in progression of Parkinson disease. Medicine (Baltimore) 98:e17478. https:\/\/doi.org\/10.1097\/MD.0000000000017478","journal-title":"Medicine (Baltimore)"},{"key":"10929_CR155","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/mds.26022","volume":"30","author":"CR Swanson","year":"2015","unstructured":"Swanson CR, Li K, Unger TL et al (2015) Lower plasma apolipoprotein A1 levels are found in Parkinson\u2019s disease and associate with apolipoprotein A1 genotype. Mov Disord 30:805\u2013812. https:\/\/doi.org\/10.1002\/mds.26022","journal-title":"Mov Disord"},{"key":"10929_CR156","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ana.23872","volume":"74","author":"JK Qiang","year":"2013","unstructured":"Qiang JK, Wong YC, Siderowf A et al (2013) Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 74:119\u2013127. https:\/\/doi.org\/10.1002\/ana.23872","journal-title":"Ann Neurol"},{"key":"10929_CR157","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00401-021-02367-3","volume":"142","author":"M Kurzawa-Akanbi","year":"2021","unstructured":"Kurzawa-Akanbi M, Tammireddy S, Fabrik I et al (2021) Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Neuropathol (Berl) 142:961\u2013984. https:\/\/doi.org\/10.1007\/s00401-021-02367-3","journal-title":"Acta Neuropathol (Berl)"},{"key":"10929_CR158","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/mds.25729","volume":"29","author":"SK Abbott","year":"2014","unstructured":"Abbott SK, Li H, Mu\u00f1oz SS et al (2014) Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson\u2019s disease. Mov Disord 29:518\u2013526. https:\/\/doi.org\/10.1002\/mds.25729","journal-title":"Mov Disord"},{"key":"10929_CR159","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10571-019-00751-y","volume":"40","author":"C Barbagallo","year":"2020","unstructured":"Barbagallo C, Mostile G, Baglieri G et al (2020) Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases. Cell Mol Neurobiol 40:531\u2013546. https:\/\/doi.org\/10.1007\/s10571-019-00751-y","journal-title":"Cell Mol Neurobiol"},{"key":"10929_CR160","doi-asserted-by":"publisher","first-page":"37043","DOI":"10.18632\/oncotarget.6158","volume":"6","author":"Y Gui","year":"2015","unstructured":"Gui Y, Liu H, Zhang L et al (2015) Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget 6:37043\u201337053. https:\/\/doi.org\/10.18632\/oncotarget.6158","journal-title":"Oncotarget"},{"key":"10929_CR161","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.ymthe.2017.08.017","volume":"25","author":"KJ McMillan","year":"2017","unstructured":"McMillan KJ, Murray TK, Bengoa-Vergniory N et al (2017) Loss of MicroRNA-7 regulation leads to \u03b1-synuclein accumulation and dopaminergic neuronal loss in vivo. Mol Ther 25:2404\u20132414. https:\/\/doi.org\/10.1016\/j.ymthe.2017.08.017","journal-title":"Mol Ther"},{"key":"10929_CR162","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neulet.2017.02.045","volume":"644","author":"X-Y Cao","year":"2017","unstructured":"Cao X-Y, Lu J-M, Zhao Z-Q et al (2017) MicroRNA biomarkers of Parkinson\u2019s disease in serum exosome-like microvesicles. Neurosci Lett 644:94\u201399. https:\/\/doi.org\/10.1016\/j.neulet.2017.02.045","journal-title":"Neurosci Lett"},{"key":"10929_CR163","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1007\/s13311-020-00842-5","volume":"17","author":"J Zou","year":"2020","unstructured":"Zou J, Guo Y, Wei L et al (2020) Long Noncoding RNA POU3F3 and \u03b1-synuclein in plasma L1CAM exosomes combined with \u03b2-glucocerebrosidase activity: potential predictors of Parkinson\u2019s disease. Neurotherapeutics 17:1104\u20131119. https:\/\/doi.org\/10.1007\/s13311-020-00842-5","journal-title":"Neurotherapeutics"},{"key":"10929_CR164","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.3390\/ijms20102373","volume":"20","author":"A Picca","year":"2019","unstructured":"Picca A, Guerra F, Calvani R et al (2019) Mitochondrial-derived vesicles as candidate biomarkers in Parkinson\u2019s disease: rationale, design and methods of the exosomes in Parkinson\u2019s disease (EXPAND) Study. Int J Mol Sci 20:2373. https:\/\/doi.org\/10.3390\/ijms20102373","journal-title":"Int J Mol Sci"},{"key":"10929_CR165","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.bbadis.2008.10.003","volume":"1792","author":"N Pavese","year":"2009","unstructured":"Pavese N, Brooks DJ (2009) Imaging neurodegeneration in Parkinson\u2019s disease. Biochim Biophys Acta BBA - Mol Basis Dis 1792:722\u2013729. https:\/\/doi.org\/10.1016\/j.bbadis.2008.10.003","journal-title":"Biochim Biophys Acta BBA - Mol Basis Dis"},{"key":"10929_CR166","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.1523\/JNEUROSCI.0189-20.2020","volume":"40","author":"WT Chu","year":"2020","unstructured":"Chu WT, DeSimone JC, Riffe CJ et al (2020) \u03b1-Synuclein induces progressive changes in brain microstructure and sensory-evoked brain function that precedes locomotor decline. J Neurosci 40:6649\u20136659. https:\/\/doi.org\/10.1523\/JNEUROSCI.0189-20.2020","journal-title":"J Neurosci"},{"key":"10929_CR167","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/ph14090847","volume":"14","author":"\u0160 Korat","year":"2021","unstructured":"Korat \u0160, Bidesi NSR, Bonanno F et al (2021) Alpha-synuclein PET tracer development\u2014an overview about current efforts. Pharmaceuticals 14:847. https:\/\/doi.org\/10.3390\/ph14090847","journal-title":"Pharmaceuticals"},{"key":"10929_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108985","volume":"208","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin S, Xiong M, Hultqvist G et al (2022) In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology 208:108985. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.108985","journal-title":"Neuropharmacology"},{"key":"10929_CR169","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2013.09.003","volume":"20","author":"MK Herbert","year":"2014","unstructured":"Herbert MK, Eeftens JM, Aerts MB et al (2014) CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat Disord 20:112\u2013115. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.09.003","journal-title":"Parkinsonism Relat Disord"},{"key":"10929_CR170","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1967\/s002449910335","volume":"19","author":"FF Calabria","year":"2016","unstructured":"Calabria FF, Calabria E, Gangemi V, Cascini GL (2016) Current status and future challenges of brain 18 imaging with F-DOPA PET for movement disorders. Hell J Nucl Med 19:33\u201341. https:\/\/doi.org\/10.1967\/s002449910335","journal-title":"Hell J Nucl Med"},{"key":"10929_CR171","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.2967\/jnumed.116.186403","volume":"58","author":"PT Meyer","year":"2017","unstructured":"Meyer PT, Frings L, R\u00fccker G, Hellwig S (2017) 18 F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 58:1888\u20131898. https:\/\/doi.org\/10.2967\/jnumed.116.186403","journal-title":"J Nucl Med"},{"key":"10929_CR172","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2967\/jnumed.116.183152","volume":"58","author":"SK Meles","year":"2017","unstructured":"Meles SK, Teune LK, De Jong BM et al (2017) Metabolic imaging in Parkinson disease. J Nucl Med 58:23\u201328. https:\/\/doi.org\/10.2967\/jnumed.116.183152","journal-title":"J Nucl Med"},{"key":"10929_CR173","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00702-019-02001-3","volume":"126","author":"R Yilmaz","year":"1996","unstructured":"Yilmaz R, Hopfner F, van Eimeren T (1996) Berg D (2019) biomarkers of Parkinson\u2019s disease: 20 years later. J Neural Transm Vienna Austria 126:803\u2013813. https:\/\/doi.org\/10.1007\/s00702-019-02001-3","journal-title":"J Neural Transm Vienna Austria"},{"key":"10929_CR174","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/brain\/awh198","volume":"127","author":"AW Michell","year":"2004","unstructured":"Michell AW (2004) Biomarkers and Parkinson\u2019s disease. Brain 127:1693\u20131705. https:\/\/doi.org\/10.1093\/brain\/awh198","journal-title":"Brain"},{"key":"10929_CR175","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.parkreldis.2015.09.048","volume":"22","author":"M Delenclos","year":"2016","unstructured":"Delenclos M, Jones DR, McLean PJ, Uitti RJ (2016) Biomarkers in Parkinson\u2019s disease: advances and strategies. Parkinsonism Relat Disord 22:S106\u2013S110. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.048","journal-title":"Parkinsonism Relat Disord"},{"key":"10929_CR176","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s13311-023-01379-z","volume":"20","author":"DG Coughlin","year":"2023","unstructured":"Coughlin DG, Irwin DJ (2023) Fluid and biopsy based biomarkers in Parkinson\u2019s disease. Neurotherapeutics 20:932\u2013954. https:\/\/doi.org\/10.1007\/s13311-023-01379-z","journal-title":"Neurotherapeutics"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10929-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10929-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10929-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T05:02:50Z","timestamp":1766898170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10929-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":176,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10929"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10929-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors that they have declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"831"}}